-
Biofrontera NasdaqCM:BFRI Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Location: 120 Presidential Way, Woburn, MA, 01801, United States | Website: https://www.biofrontera-us.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.237M
Cash
5.912M
Avg Qtr Burn
-2.568M
Short % of Float
0.83%
Insider Ownership
16.92%
Institutional Own.
24.33%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XEPI (ozenoxacin) Details Impetigo | Approved Quarterly sales | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis | Approved Quarterly sales | |
Ameluz® - PDT (3 tubes) Details Actinic keratosis | Approved Quarterly sales | |
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis) | Approved Quarterly sales | |
Ameluz®-PDT combo w/ BF-RhodoLED® Details Superficial basal cell carcinoma | Phase 3 Update | |
Ameluz® Details Actinic keratosis | Phase 3 Update | |
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis, Acne | Phase 2 Data readout |